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β-amyloid (Aβ) is produced by the β-secretase 1 (BACE1)-mediated enzymatic cleavage
of the amyloid precursor protein through the amyloidogenic pathway, making BACE1
a therapeutic target against Alzheimer’s disease (AD). Alterations in lipid metabolism
are a risk factor for AD by an unknown mechanism. The objective of this study
was to determine the effect of RNA interference against BACE1 (shBACEmiR) on
the phospholipid profile in hippocampal CA1 area in aged 3xTg-AD mice after 6 and
12 months of treatment compared to aged PS1KI mice. The shBACEmiR treatment
induced cognitive function recovery and restored mainly the fatty acid composition
of lysophosphatidylethanolamine and etherphosphatidylethanolamine, reduced the
cPLA2’s phosphorylation, down-regulated the levels of arachidonic acid and COX2 in
the hippocampi of 3xTg-AD mice. Together, our findings suggest, for the first time, that
BACE1 silencing restores phospholipids composition which could favor the recovery of
cellular homeostasis and cognitive function in the hippocampus of triple transgenic AD
mice.
Keywords: Alzheimer’s disease, phospholipids, BACE1, RNA interference, hippocampus, cognitive function
INTRODUCTION
Alzheimer’s disease (AD) is a disabling neurodegenerative disorder that impacts millions of people
worldwide and is recognized as the most common form of dementia (Querfurth and LaFerla, 2010).
The aggregation of three main neuropathological markers—senile plaques (SP), neurofibrillary
tangles (NFTs) and lipid granules—is characteristic of AD. Current evidence suggests that senile
plaques trigger the amyloid cascade and that the deposition of β-amyloid (Aβ) is the first step in
Abbreviations: AA, arachidonic acid; B, shBACE1miR; CEs, cholesterol esters; cPLA, cytosolic phospholipase
A; ePC, etherphosphatidylcholine; ePE, etherphosphatidylethanolamine; ePS, etherphosphatidylserine; LPC,
lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; m, months; PA, phosphatidic acid; PC, phosphatidylcholine;
PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; SCR, scrambled;
SM, sphingomyelin.
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the development of AD, leading to the formation of SP, NFT,
neuronal loss, and finally, clinical dementia In AD, neuronal loss
alters the cellular composition and macrostructure of cerebral
regions, either moderately, as observed in the prefrontal cortex,
or severely, as in the entorhinal cortex and hippocampus.
Progressive cell death in these regions is tightly linked to
dementia due to the reduction in the number of neurons found
in the hippocampus and cerebral cortex of individuals with AD
but not asymptomatic subjects (Andrade-Moraes et al., 2013).
Accordingly, AD patients show significantly less activation in
the hippocampal formation, which is associated with progressive
memory loss (Sperling et al., 2003).
Aβ is generated by the enzymatic processing of the amyloid
precursor protein (APP). This process involves the cleavage of
APP by the β-site APP cleavage enzyme 1 (BACE1) and the
γ-secretase complex, which contains presenilin 1 or 2 (PS1
or PS2) as the catalytic subunit to generate the Aβ40 and
Aβ42 peptides (Thinakaran and Koo, 2008). BACE1 is a type I
transmembrane aspartic protease that is related to pepsins and
retroviral proteases. The subcellular localization of BACE1 is
within the trans-Golgi network and the endosomal compartment.
Although, BACE1 reaches the plasma membrane due to vesicle
trafficking, it is quickly recycled. Only a limited amount of APP
cleavage by BACE1 takes place at the plasma membrane; the
primary BACE1-mediated APP processing occurs in endocytic
vesicles where the low pH environment favors the enzymatic
activity (Kandalepas and Vassar, 2012).
Cellular lipid composition also regulates the catalytic activity
of enzymes such as BACE1, as observed in cholesterol-rich
membrane domains known as lipid rafts (Ehehalt et al., 2003).
The cholesterol content of these membrane domains also seems
to affect the enzymatic activity of BACE1 on APP (Kalvodova
et al., 2005). However, although cholesterol is the best-studied
brain lipid in AD, many other lipids are involved in the Aβ-lipid
regulatory system, and some of these lipids exhibit stronger
effects than cholesterol on Aβ production (Di Paolo and Kim,
2011).
The association between an aberrant lipid balance and AD
is supported by the fact that the neuronal lipid composition
regulates the trafficking and activity of the membrane proteins
involved in Aβ production, such as APP, BACE1 and presenilins 1
and 2 (Grimm et al., 2005). It has also been found that high levels
of Aβ modulate the activity of enzymes such phospholipases
A2, C, and D and thus alter membrane homeostasis (Berman
et al., 2008; Oliveira and Di Paolo, 2010; Sanchez-Mejia and
Mucke, 2010). In addition, several genes related to AD, such as
APOE, ABCA7, CLU, and BIN1, are tightly connected to lipid
metabolism and cellular membrane dynamics (Hollingworth
et al., 2011; Karch and Goate, 2014; Rosenthal and Kamboh,
2014).
Although the link between lipid metabolism and AD was
suggested years ago, many aspects of this relationship have
remained elusive due to the lack of technology and analytical
methodologies to understand the molecular mechanisms of
lipid alterations in AD. The advent of lipidomics has allowed
researchers to detect and quantify the lipid species and FAs
of cerebral structures, thus facilitating the analysis of the lipid
classes involved in cell signaling, membrane structure and
trafficking. These techniques have been used to establish the
lipid compositions of brain tissues from healthy individuals
and AD patients (Han et al., 2001; Fabelo et al., 2014),
revealing changes in the levels of plasmalogens, such as, ePE,
sulfatide, ceramide, galactosylceramide, cholesterol, and alkyl-
acylglycerophosphocholine (Han et al., 2001, 2002; Cutler et al.,
2004).
Nevertheless, there is also evidence suggesting that some
of enzymes involved in AD, can regulate lipid homeostasis.
Thus, post-mortem analysis of frontal cortices from AD patients
revealed a 47% increased activity of BACE1 compared with
samples from cognitively normal individuals. They found a
positive significant linear correlation between BACE1 activity
and the levels of 4-hydroxynonenal (HNE) and malondialdehyde
(MDA) (Borghi et al., 2007). This study hints to the fact BACE1
may have a direct effect on regulating lipid homeostasis, which is
also supported by the work of Meakin et al. (2012) who used mice
lacking BACE1 gene to evaluate the effect of this enzyme on the
body weight, as well as lipid and glucose metabolism. They found
that the knockout animals had decreased production of lipids
in the body and showed increased insulin sensitivity compared
to their littermate controls, which may be an indicative of high
energy expenditure. Furthermore, experiments demonstrated
that the absence of BACE1 in brown adipose tissue and skeletal
muscle led to increased levels of the uncoupling protein 1, which
seems to be involved in protection against oxidative stress and
fatty acid handling (Meakin et al., 2012).
In addition, our previous results showed that the silencing
of BACE1 produces reduction of tauopathy in old 3xTg-AD
mice, and part of the effect was autophagosome lipidation-
dependent (Piedrahita et al., 2016). Therefore, supported in those
previous evidence about the role of BACE1 in lipid homeostasis;
our hypothesis is that BACE1 down-regulation affects the
phospholipid composition of hippocampus in an AD model. In
this study, we present the lipidomic profiles of hippocampal tissue
obtained from a commonly used transgenic mouse model of
AD (3xTg-AD) treated with RNA interference (RNAi) against
BACE1 for 6 and 12 months and compared them with control
groups, using mass spectrometry, we detected and analyzed 12
different lipid classes and subclasses, including phospholipids
(PLs), sphingolipids, lysophospholipids, plasmalogens, covering
over 402 lipid subspecies.
MATERIALS AND METHODS
RNAi Design
We designed the shRNAi sequences for silencing BACE1
(shBACE1miR). The scrambled RNAi sequences used as
control (shSCRmiR) were based on previously published
sequences (Chang et al., 2006). These sequences were cloned
into human miR-30-based stem-loops by polymerase extension
of overlapping DNA oligonucleotides. The following primers
were used for polymerase extension to clone the RNAi into
the lentiviral shuttle plasmid (pCMV-GIN-ZEO.GFP) for
transfection in HEK-293T cells: shBACE1miR forward primer,
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5′. . .CAGAAGGCTCGAGAAGGTATATGCTGTTGACAGTGA
GCGCGGACTGCAAGGAGTACAACTATAGTGAAGCCACAG
ATGTA. . .3′ and shBACE1miR reverse primer, 5′. . .CTAAAGTA
GCCCCTTGAATTCCGAGGCAGTAGGCATGGACTGCAAGG
AGTACAACTATACATCTGTGGCTTCAC. . .3′; shSCRmiR for-
ward primer, 5′. . .CAGAAGGCTCGAGAAGGTATATGCTGTT
GACTAGCACACATCAGGAAGCGCTCGACAGTGATAGTGA
AGCCACAGATGTA. . .3′, and shSCRmiR reverse primer, 5′. . .
CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA CCT
AGCACACATCAGGAAGCGCTCGACAGTGATACATCTGTG
GCTTCAC. . .3′. The extension products were digested with
XhoI and EcoRI for directional cloning into the pCMV-GIN-
ZEO.GFP vector (Open Biosystems, Pittsburg, PA, USA). To
clone the RNAi vectors for adeno-associated virus (AAV)
production, the following primers were used for polymerase
extension: shBACE1miR forward primer, 5′. . .AAAACTCGA
GGAGCTCGTGAGCGCTGGACTGCAAGGAGTACAACTCT
GTGAAGCCACAGATGGG. . .3′ and shBACE1miR reverse
primer 5′. . .TTTTGGATCCATTAATAGGCAATGGACTGCAA
GGAGTACAACTCCCATCTGTGGCTTCACAG. . .3′; shSCR-
miR forward primer, 5′. . .AAAACTCGAGTGAGCGCACCAT
CGAACCGTCAGAGTTACTGTAAAGCCACAGATGGG. . .3′
and shSCRmiR reverse primer, 5′. . .AAAAACTAGTAGGCG
TACCATCGAACCGTCAGAGTTACCCATCTGTGGCTTTAC
AG. . .3′. These extension products were digested with XhoI and
SpeI for directional cloning into a U6 expression plasmid that
was cut with XhoI and XbaI (Boudreau et al., 2009).
Viral Particle Production and Neuronal
Culture Transduction
The AAV particles were obtained by the large-scale production
of heterologous proteins from Sf9 insect cell cultures that
were co-infected with recombinant baculovirus derived from
the Autographa californica nuclear polyhedrosis virus (Urabe
et al., 2002). The shBACE1miR expression cassettes—driven by
the mouse U6 promoter—were cloned into pAAV.CMV.hrGFP,
which contained AAV serotype 2/5 inverted terminal repeats
and a CMV-humanized Renilla GFP (hrGFP)-simian virus 40
poly (A) reporter cassette (Urabe et al., 2002). The AAV titers
were determined using quantitative PCR and/or DNA slot blot
analysis. The AAV particles were dialyzed before use.
Animal Procedures
We used 3xTg-AD mice containing PS1 (M146V), APP (Swe),
and tau (P301L) mutations (Oddo et al., 2003), as well as
the PS1KI mice containing the PS1 (M146V) mutation, named
as “control group,” because PS1KI is the genetic background
of the 3xTg-AD mice, do not develop intracellular and
extracellular β-Amyloid aggregation and do not exhibit LTP
deficits. Furthermore, those mice are viable, fertile, normal in size
and do not display any gross physical or behavioral abnormalities
(Oddo et al., 2003). Both mice strains were kindly donated
by Dr. Frank M LaFerla from the University of California
(Irvine, CA, USA). The animals were bred in-house in a specific
pathogen-free (SPF) colony at the vivarium at SIU (Sede de
Investigación Universitaria, University of Antioquia, Medellin,
Colombia), maintained with a 12 h:12 h dark:light cycle, and
received food and water ad libitum. The animals were handled
in accordance with the Colombian standards (Law 84/1989 and
resolution 8430/1993) and NIH guidelines for animal welfare
and care (Public Law 99-158, November 20, 1985, “Animals in
Research”). Specific care was taken to minimize animal suffering
and minimize the number of animals used. A total of 42 3xTg-
AD mice (6 and 12 months old, 20–30 g), 20 PS1KI mice (6 and
12 months old, 20–30 g) were used. 28 males and 14 females mice
were aleatorially assigned, using three males and 2–3 females
per group. One side of the hippocampi was used for lipidomic
analysis and the other for biochemical analysis.
The animals were anesthetized (5% ketamine and 2%
xylazine, 50:5 dosage mg/kg) and bilaterally injected with
1 µL of AAV2-shSCRmiR (shSCRmiR) or AAV2-shBACE1miR
(shBACE1miR) into both hippocampi (bregma coordinates were
−1.7 anteroposterior, 0.8 (right) and −0.8 (left) lateral, and
2.5 mm dorsoventral). The injections were performed with
a 10-µL syringe (Hamilton, Reno, NV, USA) at 0.1 µL/min,
and 10 min elapsed after the infusion before the syringe was
withdrawn. The following experimental groups were used:, Short-
term treatment group, PS1KI and 3xTg-AD mice were injected
with shBACE1miR (B12m) or scrambled miR (Scr12m) at an
age of 12 months old and evaluated 6 months later; and Long-
term treatment group, PS1KI and 3xTg-AD mice injected with
shBACE1miR (B6m) and scrambled miR (Scr6m) at an age
of 6 months and evaluated 1 year after injection (Figure 1).
The animals were evaluated by the Morris water maze test and
later sacrificed for biochemical measurements (Figure 1). The
hippocampi were dissected, immediately frozen on dry ice and
stored at−80◦C until use.
Morris Water Maze Test
Morris water maze testing was performed at 6 and 12 months
following the shBACE1miR and shSCRmiR injection in the
PS1KI and 3xTg-AD mice. A circular white pool (1-m diameter
and 0.5-m height) was filled with water at 22 ± 2◦C, and a white
escape platform with a diameter of 20 cm was submerged 2 cm
below the water surface. This platform was hidden, because the
water was colored white with non-toxic opaque paint to facilitate
video recording. The test procedure consisted of four stages: (1)
Visible: 2 days, two trials per day, 60 s per trial with the platform
2 cm above the water level; (2) Learning: 5 days, two trials per day
(10 trials in total), 60 s per trial to find the hidden platform; (3)
Retention: 48 h after the last training day (1 day, one trial per day,
60 s per trial without platform); and (4) Transference (changing
location of the platform to the opposite side of the pool): a second
learning trial of 2 days, two trials per day (four trials in total),
60 s per trial to find the hidden platform (Figure 1). The animal
behavioral tests were recorded and analyzed individually using
View Point software (Lyon, France).
Lipid Analyses
The total lipids from the mouse hippocampus were extracted
according to the FOLCH technique (Folch et al., 1957) using
a mixture of 2 mL of chloroform (CHCl3) and 1 mL of
methanol (MeOH) in a 2:1 (v/v) ratio. Then, 0.005% butylated
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FIGURE 1 | Experimental design. AAVshSCRmiR and AAVshBACEmiR were injected in the hippocampus of 6 and 12 months-old PS1KI and 3xTg-AD mice.
After, 12 and 6 months post-injection respectively, behavioral analyses using Morris water maze test were realized. First and second days visible test; Learning and
memory were evaluate during 5 days (10 trials); after 48 h retention test was realized. Afterward, the transfer test was performed over 2 days (four trials).
hydroxytoluene (BHT) was added, and this mixture was used
to homogenize the hippocampus. Subsequently, 1 mL of 0.9%
NaCl was added, and the mixture was centrifuged at 3000 rpm
for 3 min. The organic layer (lower layer) was removed and
transferred to a new glass tube. This procedure was performed
in an oxygen-free using enriched nitrogen environment to avoid
lipid oxidation processes and was repeated three times. The
solvents were evaporated, and the extract was lyophilized to
remove the excess of humidity. Finally, the lipid composition was
analyzed by mass spectrometry.
Mass Spectrometry
An automated ESI-MS/MS approach was used and data
acquisition and analysis carried out at the Kansas Lipidomics
Research Center using an API 4000TM and Q-TRAP (4000Qtrap)
detection system as described previously (Sparkes et al.,
2010; Zhou et al., 2011). This protocol allowed the detection
and quantification of low concentrations of the polar lipid
compounds. The molecules were determined by the mass/charge
ratios, which were compared with the respective internal
standard to determine which species of lipids were present in
the evaluated extract: 0.66 nmol di14:0-PC, 0.66 nmol di24:1-PC,
0.66 nmol 13:0-lysoPC, 0.66 nmol 19:0-lysoPC, 0.36 nmol di14:0-
PE, 0.36 nmol di24:1-PE, 0.36 nmol 14:0-lysoPE, 0.36 nmol
18:0-lysoPE, 0.36 nmol 14:0-lysoPG, 0.36 nmol 18:0- lysoPG,
0.36 nmol di14:0-PA, 0.36 nmol di20:0(phytanoyl)-PA, 0.24 nmol
di14:0-PS, 0.24 nmol di20:0 (phytanoyl)-PS, 0.20 nmol 16:0-18:0-
PI, 0.16 nmol di18:0-PI, and 1 nmol 15:0 fatty acid. The system
detected a total of 12 different lipid species and their respective
sub-species, which were identified by the number of carbons
and degree of unsaturation of the chain. Lipid concentration was
normalized by molar concentration across all species for each
sample, and the final data are presented as mean mol%.
Western Blotting Analysis
The animals were sacrificed, and the cerebral cortices were
dissected, immediately frozen in liquid nitrogen, and stored at
−80◦C prior to use. The samples were lysed in 10 mM Tris
(pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10%
glycerol, 1% NP40, 1 nM orthovanadate, 5 mM NaF, 1 mM
phenylmethylsulfonyl fluoride, and a protease inhibitor cocktail
(Sigma-Aldrich) (Cardona-Gomez et al., 2004). The lysates
(containing approximately 40µg of proteins, quantified using the
Bradford method) were loaded onto 8 and 10% polyacrilamide
gels and transferred onto nitrocellulose membranes (GE
Healthcare) at 250 mA for 2 h using an electrophoretic transfer
system. The membranes were incubated overnight at 4◦C in
anti phospho-cPLA2 (Ser505) (rabbit polyclonal. 1:1000; Cell
Signaling), anti-COX2 (rabbit polyclonal. 1:500; abcam), and
mouse anti-βIII tubulin (1:5000; Promega). IRDye 800CW goat
anti-rabbit (LI-COR; 1:5000) were used as the secondary probes.
The blots were developed using the Odyssey Infrared Imaging
System. To minimize inter-assay variation, samples from all of
the experimental groups were processed in parallel.
Statistical Analysis
In the behavioral test were used 10–15 animals/group. The
escape latency during the hidden platform training sessions
and transference tests were determined using repeated-measures
ANOVA. The latency and the number of platform crosses in the
hidden platform trials and in the probe trials were analyzed by
one-way ANOVA, also ANOVA per day followed by Fisher’s post
hoc test were realized. The analyses were performed using SPSS
18.0 software (Chicago, IL, USA). The values were expressed as
the mean ± SEM. The results were considered to be significant
at ∗p < 0.05, and ∗∗p < 0.01. All of the sample groups were
processed in parallel to reduce inter-assay variation.
The lipid levels for each sample were calculated by summing
the total number of moles of all lipid species measured and
then normalizing that total to mol%. Comparisons between
groups were assessed either by one-way ANOVA, followed
by the Tukey post hoc test or the Kruskal–Wallis test,
depending on the homoscedasticity and normality of the
experimental data. Multivariate statistics were performed using
principal component analysis (PCA) and a partial least squares-
discriminant analysis (PLS-DA) (Barker and Rayens, 2003). PLS-
DA was included because it is particularly suitable for the analysis
of datasets with a small number of samples and a large number
of variables. The PLS-DA analysis was carried out using the
routines described in (Ballabio and Consonni, 2013). For both
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techniques, an index representing the importance of the variables
according to the first components was estimated. PCA used an
index (denoted as ρ) that considers the entries of the principal
directions and the variance of each component to determine
the weight that every lipid species has in the estimation of the
principal directions (Jolliffe, 2002). In contrast, for PLS-DA, the
index used is called the variable importance in projection (VIP)
(Mehmood et al., 2012), which analogously to ρ, determines the
importance of each variable that is reflected by each component
and also considers the variance explained by each PLS component
(for a detailed description of VIP, please refer to Mehmood and
the references therein). The confidence ellipsoids per group and
treatment are also included. The data from the univariate and
bivariate statistics are expressed as the mean± the standard error
of the mean. The statistical significance is indicated in the figures
and tables.
RESULTS
BACE1 Gene Silencing Prevents
Learning and Memory Impairments in
3xTg-AD Mice after 6 and 12 months of
Treatment
During the visible platform test, the shBACE1miR-treated 3xTg-
AD mice did not show differences compared to the controls
after either 6 or 12 months of treatment (Figure 2A). However,
the learning task performance of the shBACE1miR-treated
mice at 6 and 12 months post-injection was better than
that of the corresponding shSCRmiR-treated 3xTg-AD control
mice (Figure 2B). These observations supported a memory
improvement because the shBACE1miR-treated mice spent less
time finding the hidden platform and showed preferences in the
trajectory for the quadrant of the platform (Figures 2C,D) at both
post-injection time points. Additionally, reversal learning skills
were improved in the 3xTgAD mice treated with shBACE1miR,
which spent less time looking for the second platform location
in the transfer test than the shSCRmiR-treated 3xTgAD mice
(Figure 2E). PS1KI mice treated with shBACE1miR did not show
changes respect to the untreated control in both evaluated time
lines (Figure 2).
The Phospholipid Profile of the
Hippocampus Is Altered in 3xTg-AD Mice
To determine whether the transduction with shBACE1miR or the
scrambled version induced lipid changes in the 3xTg-AD mice,
we characterized the hippocampal phospholipid composition
of the transgenic animals at two different post-injection time
points (6 and 12 months). These profiles were compared with
shBACE1miR or the scrambled treated PS1KI mice, which were
evaluated at the same post-injection times. At a glance, the
analysis revealed two types of variations in the phospholipid
contents of the 3xTg-AD mouse hippocampus. The first set of
changes seems to be related to the pathological condition, while
the second type is associated with the shBACE1miR treatment.
The lipid profiling of the all control groups PS1KI and 3xTg-
AD mice hippocampus shows that the lipidome is primarily
composed of high abundance glycerophospholipids, such as PC
(47.5 and 47.2%), PS (5.1 and 5.8%), PE (18.6 and 20.0%), and PI
(1.9 and 1.8%); sphingolipids, such as SM-DSM (8.0 and 8.3%);
low abundance glycerophospholipids, such as PA (0.3 and 0.4%)
and PG (0.07 and 0.6%); lysophospholipids, such as LPC (0.2 and
0.4%) and LPE (0.9 and 1.0%); and etherphospholids, such as ePC
(1.4 and 1.6%), ePS (0.02 and 0.11%), and ePE (1.4 and 1.6%)
(Figure 3A).
The treatment of 3xTg-AD mice with the shBACE1miR or
shSCRmiR for 6 or 12 months resulted in distinctive lipid profiles
compared with the control animals (Figure 3A). The disease-
associated changes in the phospholipid composition involve an
overall decrease in PC (control vs. AD mice, p < 0.001), PS
(control vs. AD mice, p < 0.01) PE (control vs. AD mice,
p < 0.01), PI (control vs. AD mice, p < 0.01), and SM-DSM
(control vs. AD mice, p < 0.05) (Figure 3A). In contrast, the lipid
profile obtained from the shBACE1miR-treated 3xTg-AD mice
showed that the treatment restored the LPE (p < 0.001) and ePE
(p < 0.05) content to basal levels (Figures 3A,B), suggesting a
regulatory role for BACE1 in the biosynthesis of these particular
plasmalogens.
The results of the PCA analyses from the detected lipids
indicate that nearly 82% of the total variance may be explained by
the first two principal components (PC1 and PC2) (Figure 3B).
The most relevant variables for these two components were
related to the PC subclasses 32:0 and PE subclasses 40:6,
which demonstrated higher ρ indexes (13.6236 and 12.1049
respectively) (Figure 3B). PC 32:0 is composed of the saturated
FA Palmitic acid (Figure 3B). In contrast, PE 40:6 is composed
of the polyunsaturated FAs DHA and saturated FAs stearic acid
(Figure 3B). The PLS-DA analyses indicate that nearly 86% of
the total variance may be explained by factor 1. In this case,
the most relevant feature according to VIP are PI 40:00 (VIP:
2.0965) and PC 44:8 (VIP = 1.9355). Moreover, three of the
first five most relevant features according to VIP belong to the
LPE species (Figure 3B). This LPE subclass is composed of the
monounsaturated FA such as Palmitoleic (16:1), Oleic (18:1)
and polyunsaturated AA acids, as arachidonic (20:4). Both the
PCA and PLS-DA analyses indicate that the control group is
located in a different quadrant of the plane compared with the
AD and treated AD animals, which are in the right quadrant of
the graphic (Figure 3B). In addition, the AD and treated AD
groups also show a different distribution pattern, indicating that
BACE1 silencing modifies the course of certain PLs in the disease
(Figure 3B).
shBACE1miR Restores the Basal Levels
of LPE and ePE of 3xTg-AD at 6 and
12 months Post-injection
We demonstrated that shBACE1miR has a regulatory effect
on the lipid profile in two specific lipid classes: LPE and
ePE. The LPE levels increased (p < 0.001) in the AD groups
compared with the AD mice treated with the shBACE1miR and
the control groups (Figures 3A and 4A). The PCA analysis
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FIGURE 2 | BACE1miR prevents cognitive dysfunction in 3xTg-AD mice. The learning and memory task performance of the PS1KI and 3xTg-AD mice were
evaluated by the Morris water maze test after 6 and 12 months of treatment with shBACE1miR and compared with the respective animal controls. (A) Visible test,
(B) Learning test (first position of the platform), (C,D) Retention and representative trajectory images of the animals during the retention test, and (E) Transference
test (second position of the platform), The data are expressed as the group mean ± SEM. ∗p < 0.05, ∗∗p < 0.001; n = 12 to 10–15 animals/group.
showed that the AD+shBACE1miR group had a displacement
to the left quadrant close to the control group, while the
AD mice occupy a different region that is shifted to the
right (Figure 4A). This result indicates that nearly 97% of
the total variance may be explained by the first two principal
components (PC1 and PC2), which is LPE 18:1 according to
ρ= 1.0208. However, three of the first five most relevant features
according to VIP belong to unsaturated lipid species (22:6, 20:1,
and 20:4) (Figure 4A). In addition, these observations were
confirmed by counter plot analyses, where the LPE content was
increased in the AD groups (3xTg-Scr6m and 3xTg-Scr12m)
and restored to the basal levels in the shBACE1miR-treated
AD mice at 6 and 12 months post-injection (Figure 4B).
The PLS-DA analysis also revealed that the AD+shBACE1miR
group on the graph had a displacement from AD to control
group; however, the AD group exhibited a different distribution.
The subclasses with major importance in data distribution,
based on higher ρ index, were LPE 22:5 (docosapentaenoic
acid) (1.0858) and LPE 20:2 (Eicosadienoic Acid) (1.0494)
(Figure 4A).
In addition, ePE also seems to be affected by the treatment
because the levels of this plasmalogen decreased (p < 0.05) in
AD compared with the AD+shBACE1miR and control groups
(Figure 3A). The PCA analysis confirmed this result and showed
that all experimental groups occupy different areas in the
quadrants, i.e., ePE species were able to differentiate among the
experimental groups. The most relevant molecular species, such
as ePE 40:6 (18:0 stearic/22:6 DHA) and 38:6 (16:0 palmitic/22:6
DHA), had a higher ρ index (0,01470 and 1,1170, respectively)
(Figure 5A). Interestingly, the contour graphic showed changes
in the same ePE subclasses and showed a decrease in AD groups,
although their levels were recovered in the AD+shBACE1miR
groups at 6 and 12 months post-treatment (Figure 5B). The
recovery of the basal levels may represent a modulatory effect
of the shBACE1miR on the phospholipid profile in the 3xTg-
AD mice. The PLS-DA analysis also demonstrated different
distribution patterns for all groups on the plot. The subclasses
with major importance in the data distribution based on a high
VIP index were ePE 38:6 (16:0 palmitic acid/22:6 DHA) (1.5995),
ePE 40:6 (22:6 DHA/18:0 stearic) (1.4983) and (Figure 5A).
A detailed analysis of the LPE’s FA composition revealed the
presence of large chain fatty acyls (16C to 22C) with either
monounsaturated or polyunsaturated FAs bearing 1, 4, or 6
bonds. Interestingly, the shBACE1miR treatment modified the
carbon-chain length and the degree of unsaturation of the LPE
subspecies. shBACE1miR seemed to restore the basal levels of
long fatty acyls chains, such as 16C, 18C, 20C and 22C, which
were altered in the untreated AD groups (3xTg-Scr6m and 3xTg-
Scr12m) (Figure 6A). The same effect was also found for the
degree of unsaturation, particularly in polyunsaturated FAs with
1, 4 or 6 bonds, compared with the control groups (Figure 6B).
In contrast, the FA composition analysis of ePE showed that
this plasmalogen was formed by very long fatty acyls chains
(32C to 40C), whose levels did not show statistically significant
differences among the experimental groups (Figure 6C). In
contrast, the analysis of the FA unsaturation number revealed
changes in ePE FAs with six bonds (Figure 6D). It was evident
that the shBACE1miR treatment (3xTg-B6m and 3xTg-B12m)
partially restored this type of unsaturation in the ePE FAs to that
observed in all control groups (Figure 6D).
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FIGURE 3 | Lipid composition of the hippocampus from 3xTg-AD and control mice, grouped according to the time of treatment. Various lipid changes
can be seen in the hippocampal tissue. (A) The lipid class profiles are expressed as %mol composition. All lipid species were measured (means), and the error bars
represent the SEM. The data for the 3xTg-AD mice were significantly different from the control groups (∗p < 0.05, ∗∗p < 0.01; ∗∗∗p < 0.001 ANOVA followed by the
Tukey post hoc test or Kruskal–Wallis test). (B) Multivariate analyses of the lipid profiles from the hippocampus. PCA, principal component analyses for the lipid
classes; PLS-DA, partial least squares analysis to discriminate between the lipid classes. The left panels illustrate the factor loadings for PC1 and PC2, with the
indices of variance explained for each component. The right panels show the factor score plots for PLS-DA. The variables in the analyses are the controls, AD
(3xTg-AD without treatment) and AD+shBACE1-miR (3xTg-AD with 6 and 12 months of treatment). PA, phosphatidic acid; PC, phosphatidylcholine; LPC,
lysophosphatidylcholine; ePC etherphosphatidylcholine; PS, phosphatidylserine; ePS, etherphosphatidylserine; PE, phosphatidylethanolamine; LPE,
lysophosphatidylethanolamine; ePE, etherphosphatidylethanolamine, PI, phosphatidylinositol; PG, phosphatidylglycerol; SM, sphingomyelin. n = 3–5 per group.
BACE1 Silencing Reduces Active cPLA2,
ARA, and COX2 Levels
The LPE and ePE level changes suggested a potential implication
of a PLA2 isoform (Dennis et al., 2011), to understand this
effect we evaluated the phosphorylation of cPLA, AA levels
and COX2 protein levels in all experimental groups, after
confirming the decreased BACE1 protein levels (p < 0.01)
in the hippocampi from shBACE1miR treated mice respect
to those treated with shSCRmiR (Figure 7A). BACE1 protein
levels had a tendency to increase under PS1KI condition, but
without significant effect, as reported Giliberto et al. (2009).
cPLA2 is the main enzyme involved in the production of both
lipids species (Makide et al., 2009), inducing AA release, which
trigger proinflammatory signaling through the cyclooxygenases,
as COX2 (Lin et al., 1993; Kuwata et al., 1998). Our findings
evidenced that the levels of phosphorylated cPLA2 in ser505
were decreased at 6 and 12 months post-injection in the
shBACEmiR groups compared with Scr (p < 0.01) and PS1KI
controls group (p < 0.05) (Figure 7B). The AA levels were
increased in AD (3xTg-Scr6 and Scr12m) groups, how has been
previously described (Sanchez-Mejia and Mucke, 2010), while
shBACE1miR6 and shBACE1miR12 decreased to control levels
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FIGURE 4 | shBACE1miR restores the basal levels of LPE at 6 and 12 months post-injection. (A) PCA, Principal component analyses for the LPE subclasses
and PLS-DA, Partial least squares method to discriminate between the LPE subclasses. The left panels illustrate the factor loadings for PC1 and PC2, with the
indices of variance explained for each component. The right panels show the factor score plots for PLS-DA. The groups in the analyses are controls, AD (3xTg-AD
without treatment) and AD+shBACE1-miR (3xTg-AD with 6 and 12 months of treatment). (B) Contour plots of the more influential subclasses of LPE (variables) in the
discriminant analyses for each evaluated variable; all LPE and ePE subclasses were measured (means), and the error bars represent the SEM. n = 3–5 per group.
FIGURE 5 | shBACE1miR recovers the basal levels of ePE at 6 and 12 months post-injection. (A) PCA, principal component analyses for the ePE
subclasses; PLS-DA, partial least squares method to discriminate between the ePE subclasses. The left panels illustrate the factor loadings for PC1 and PC2, with
the indices of variance explained for each component. The right panels show the factor score plots for PLS-DA. The groups in the analyses are controls, AD
(3xTg-AD without treatment) and AD+shBACE1-miR (3xTg-AD with 6 and 12 months of treatment). (B) Contour plots of the more influential subclasses of ePE
(variables) in the discriminant analyses for each evaluated variable; all ePE subclasses were measured (means), and the error bars represent the SEM. n = 3–5 per
group.
(p < 0.001) (Figure 7C). Finally, we found that COX2 levels
increased significantly in all the 3xTg-AD groups; however,
this decreased only at the long-term shBACE1miR- treatment
(12 m) (Figure 7D). Taken together, these results suggest that
the BACE1 silencing reduces the composition of AA in LPE at
6 and 12 months of treatment, with a clear repercussion on anti-
inflammatory response at 12 months by decrease of cPLA2 and
COX2 levels in the hippocampus from 3xTg-AD mice.
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FIGURE 6 | Altered fatty acid composition of LPE and ePE in the hippocampal region from the 3xTg-AD mouse models and recovery by BACE1miR.
Independent analyses of changes in lysophospholipid (LPE) and plasmalogen (ePE) chain lengths equal to the total number of carbon atoms in the fatty acid moieties
(A,C), and the LPE and ePE saturation equal to the total number of double bonds in the fatty acid moieties (B,D). The data for the 3xTg-AD mice were significantly
different from those of the control groups (∗p < 0.05, ∗∗p < 0.01; ANOVA followed by the Tukey post hoc test or Kruskal–Wallis test). #p < 0.05, ANOVA with
Tukey’s tests compared between 3xTg-AD groups. Data are expressed as Mol %. n = 3–5 per group.
DISCUSSION
Our findings suggest by the first time that the long-term silencing
of BACE1 prevents the learning and memory impairment
in 3xTg-AD mice, by restoration of the composition of PE
derivates, as LPE and ePE, and the subsequent blocking of
the pro-inflammatory activation of cPLA2/AA/COX- 2 pathway
in the hippocampus. In agreement with our previous studies,
this BACE1 knock-down’s effect could be also related to the
reduction of the hyperphosphorylation of tau and recovery of PE-
dependent autophagosome formation (Piedrahita et al., 2016);
since those processes are progressively affected in the 3xTg-AD
mice at 12 and 18 months old (Villamil-Ortiz and Cardona-
Gomez, 2015).
Recently, we validated the silencing of BACE1 in wild type
and triple transgenic AD mice, where shBACE1miR treatment
induced neuroprotection by reduction of CTF (carboxy-terminal
fragment) and 1–42 Aβ levels. In addition, hyperphosphorylated
tau was reduced through the regulation of some autophagy actors,
which were blocked by PE lipidation inhibitor [3 Methyl-Adenine
(3MA)] (Piedrahita et al., 2016). Therefore, in the present study,
we performed a deep lipid profile analysis of the hippocampal
region of 3xTg-AD mice to evaluate the effect of BACE1 silencing
in this AD model, whose treatment improved the spatial learning
and memory skills at 6 and 12 months post-injection. BACE1
inhibition has several substrates involved in neurotransmission,
excitability and synapses, as neuroregulin 1, APP, between
others (Munro et al., 2016), and its inhibition could be adverse
(Vassar, 2014; Ohno, 2016). However, a reduction of BACE1
protein under a pathological over-expressed BACE1 activity
condition, could suggest an important benefit in neuroprotection,
remyelination and plasticity (Farah et al., 2011; Piedrahita et al.,
2016), supported by the recovery of the cognitive function in the
shBACE1miR treated 3xTg-AD mice. Also, BACE1’s silencing did
not affect the performance of PS1KI mice and it had a lipid profile
very similar than C57BL6 mice (Supplementary Figure S1).
We detected 12 lipid classes that covered over 402 lipid
subclasses, observing changes in 6 PL classes in the hippocampus
of the 3xTg-AD mice compared to the control groups.
Interestingly, we observed that treatment with shBACE1miR
modifies the levels of LPE and ePE, restoring the amounts of
these plasmalogens to the basal levels found in the control
animals, which may be associated with tissue homeostasis and
cognitive function recovery. In addition, there were also changes
in the individual lipid species of different subclasses, suggesting
that the FA carbon chain and unsaturation number may play
an important role in AD pathogenesis. These results suggest
that the numerous changes that occurred in the PLs could be
used as potential molecular target that facilitate understanding
the biochemical mechanism involved in the neurodegenerative
process in AD.
Alterations in membrane lipids are widely described in brains
from AD and several neurodegenerative disorders (Sagin and
Sozmen, 2008). A tight relationship has been established between
lipid metabolism and lipotoxicity in neurons (Du et al., 2009).
Trafficking and secretase activity of the key membrane-bound
proteins controlling Aβ levels, including APP, BACE1, and
presenilins, are regulated by membrane levels of cholesterol
and SM. According to early studies, a general decline of SM
content in AD brains has been described (Cunnane et al., 2012),
which was confirmed by decreased levels of SM in the 3xTgAD
mice groups in our data. Also, different studies have reported
decreased brain PL levels in neurodegenerative diseases, mainly
PI (Prasad et al., 1998; Berman et al., 2008; Whiley et al., 2014);
PC (Whiley et al., 2014) PE and its derivatives, such as LPE
and ePE (Ginsberg et al., 1993, 1995; Nesic et al., 2012); and PS
(Shea, 1997), seeming to have multifactorial origins, including the
hyperactivation of phospholipases, peroxisomal dysfunction and
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FIGURE 7 | shBACEmiR decreases the levels of phosphorylated cPLA2, ARA and COX2 levels in the hippocampus of old 3xTg-AD mice’s.
(A) Representative bands from BACE1 protein levels and (B) p-cPLA2 levels at long and short-term shBACE1miR’s post-treatment (6 and 12 months) by Western
blotting. (C) Arachidonic acid composition levels in LPE lipid. Results are expressed as Mol % of total fatty acids. (D) Representative immunoblot of COX2 protein
levels. Results are expressed as relative units (RU) and. Data are shown as mean ± SEM. For 3xTg-AD, results were significantly different from the controls group
(∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; ANOVA followed by Tukey post hoc test). n = 3–5 per group.
irregular FA composition of PLs. Our observations confirm those
results, where alterations in PL metabolism were close related to
AD condition, whose aberrant metabolism could be reflected in
the animal’s behavior alteration.
In the present study, we observed decreased levels of PC
in all AD groups compared with the control groups, specially
the subspecies 34:1 and 32:0. The alterations in the PC levels
have been described as a deregulation in the diacylglycerol
cholinotransferase-mediated biosynthesis and turnover of PC
from DAG, which affects neurite and axonal outgrowth and
synaptic plasticity by DAG accumulation and low levels of
PC (Araki and Wurtman, 1997; Mateos et al., 2010; Gaudin
et al., 2012). However, the biological activity depends on the
type of FA linked to the molecular structure. Previous works
reported that these PCs are decreased in micro-extracted senile
plaques from the post-mortem AD brain, and it could be linked
to the roles of PLA2 and PLD1 in Aβ activation (Gaudin
et al., 2012; Whiley et al., 2014). Additionally, these species are
composed of monounsaturated omega-9 oleic acid (18:1 n-9) and
saturated palmitic acid (16:0), and this composition of membrane
lipids influences their biophysical properties, including fluidity,
permeability and charge (Finkelstein et al., 2014). The loss of oleic
acid has been reported to favor BACE1 activity and increase the
Aβ 1-42/Aβ 1-40 ratio, whereas dietary oleic acid supplements
increased the Aβ 1-40/Aβ 1-42 ratio and reduced the levels of
BACE and presenilin, as well as the number of amyloid plaques in
AD brains (Amtul et al., 2011). Interestingly, our results confirm
the aberrant biosynthesis of PC and the imbalance between the
levels of saturated/unsaturated FAs affecting to the structure of
PC could favor the abnormal destabilization of membrane in AD
brains.
Also, in our work, we found decreased PS and PE levels in the
hippocampus from all AD’s experimental groups. Interestingly,
we observed that the main decreased FA in both species was
40:6, which is composed of 22:6 (DHA) and 18:0 (stearic
acid) chains. DHA is the best substrate for PS biosynthesis,
and a decrease in this polyunsaturated acid has been related
to cognitive impairment (Grimm et al., 2013). Reduction in
the DHA levels of hippocampal PS was demonstrated in
senescence accelerated mice model, which has a short life span,
memory and learning alterations, and increased amounts of
hippocampal Aβ plaques. In addition, DHA content of PS
and PE are 12 and 14% reduced in the human AD’s cortex
respectively, and also it has been found less amount of PE
subspecies 22:6 n-3 (DHA) in the cortex of 9-month-old AD
mice (Cunnane et al., 2012). In general, a reduction of PE, PE-
derived PUFAs in the brain (Ginsberg et al., 1993; Conquer
et al., 2000; Dorninger et al., 2015) and in plasma (Conquer
et al., 2000) has been associated to AD. Therefore, our results
are in agreement with the previous findings and suggest that
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altered PS and PE metabolism in the hippocampus could be
implied in the cognitive impairment described in AD by affecting
the signaling pathways modulated by PUFAs, such as DHA
and AA.
PE accounts for approximately 25% of mammalian PLs and
is significantly enriched in the brain, where the PE content is
45% of the total PLs. PE has been recently involved in the
positive regulation of autophagy and longevity (Rockenfeller
et al., 2015). PEs and/or PE-derived (LPE and ePE) are
essentials in the cell function (Vance and Tasseva, 2013),
LPE can be generated from PE via a phospholipase A-type
reaction (Vance and Tasseva, 2013). Currently, the physiological
significance of LPE in the brain is unknown. However, in
non-mammalian species, it has been attributed to certain
functions. For example, in the housefly, LPE has antifungal
and antibacterial activity (Meylaers et al., 2004), and in the
mushroom Grifola frondosa, it stimulates mitogen-activated
protein kinase (MAPK) signaling. Furthermore, was reported
that LPE induced neuronal differentiation of PC12 cells (Nishina
et al., 2006). And recently it has been reported that LPE
has a direct relationship with the calcium influx (Lee et al.,
2015), which is close related to cell death (Bezprozvanny
and Mattson, 2008). Interestingly, our data indicated increased
LPE levels in the hippocampus of AD animals (Scr6 m
and Scr12 m), specifically, the AA (20:4), the DHA (22:6)
and the oleic acid (18:1) composition. Surprisingly, BACE1
silencing for 6 and 12 months reestablished the levels of
these FAs to the control levels, which suggested that LPE is
accumulated in AD. In addition, The PLS-DA analysis of the
phospholipid species, also suggested that, the shBACE1miR
treatment generated a displacement of lipid prolife from AD
group to control group profile. According to PLS-DA, such
displacement is explained in an important part by LPE (16:1,
18:1, 20:4), meaning a significant role of BACE1 silencing in
neuroprotection.
Although, DHA is widely reported as being beneficial for
cells, the excess levels likely trigger a negative effect on the
membrane balance because the DHA content in the plasma
membrane of T27A cells may be detrimental. This prediction
was confirmed by observations of the reduced viability of cells
incubated with 22:6/18:0 (Zerouga et al., 1996). In contrast,
the key enzyme involved in the turnover and degradation
of LPE, phospholipase A2 (PLA2), is markedly increased in
brains from AD patients (Farooqui, 2010) and associated to
AA production in AD (Sanchez-Mejia and Mucke, 2010). Also,
PLA2 activation has been linked to inflammation process in
a genetically model of neurodegeneration, since it showed
that specific lysophospholipids were responsible for microglial
activation and the cytosolic PLA2 (cPLA2) inhibition had
neuroprotective effect (Lee et al., 2011; Sundaram et al., 2012).
According to our results, BACE1 silencing down-regulated the
composition of AA in LPE at 6 and 12 months post-treatment,
and decreased the phosphorylation state of cPLA2, which could
be involved in the cell membrane homeostasis of treated AD
mice at 12 months post-injection, with the consequent down-
regulation of AA levels and COX2 pro-inflammatory pathway
in the same time-line (Figures 7C,D), suggesting a more
effective anti-inflammatory regulation by the long-term BACE1’s
silencing. Which are in concordance with our recent data were
BACE1 silencing reduced not only β-amyloid and CTF, but
also reduced MAPK activity and phosphorylated soluble tau
(Piedrahita et al., 2016). MAPK regulates cPLA2 activity down-
stream under lipid peroxidation condition (Lee et al., 2011). Also,
cPLA2 activity has been involved in the hyperphosphorylation
of tau during neuroinflammation (Sundaram et al., 2012). AA
through COX2 activity is the precursor of pro-inflammatory
eicosanoids, prostaglandin E2 and leukotriene B4 and also
increases the production of interleukin-1, tumor necrosis factor-
α and IL-6 (SanGiovanni and Chew, 2005; Freund-Levi et al.,
2014).
On the other side, also it has been reported that 22:6
FA suppresses the production of AA-derived eicosanoids and
thus exerts anti-inflammatory and immunosuppressive effects
(Calder, 2012). Decreased levels of 22:6 trigger oxidative stress,
which is known as a primary factor in the pathogenesis of
AD because of the high-metabolic rate of the brain, which
makes it particularly susceptible to ROS (Migliore et al.,
2005). Also, oxidative stress is related to the progressive
degradation of brain PLs in AD because they are rich in
readily oxidizable AAs and DHAs (SanGiovanni and Chew,
2005; Calder, 2012). However, our data suggest a membrane
destabilization process showing an up-regulation of DHA 22:6 in
the LPE composition, maybe contributing to the pathogenesis of
AD. Interestingly our data suggest that the BACE1 knock-down
reverse this pathogenic environment, generating homeostasis on
FA composition of LPE, and reducing pro-inflammatory pathway
cPLA2/AA/COX-2.
On the complementary side, a deficiency in brain ePE, which
constitutes up to 70% of the total plasmalogens, has been
traditionally associated with AD development, and low levels
have been detected in the brain (Braverman and Moser, 2012),
in the cerebrospinal fluid (Brites et al., 2009; Andrade-Moraes
et al., 2013) and in the serum of patients (Lessig and Fuchs,
2009); supporting the importance of those ones to control the
membrane instability during oxidative stress in AD. According to
our results, the reduction in ePE levels resulted from a significant
decrease in the polyunsaturated 22:6 (DHA) and 18:0 (oleic
acid) FAs. Because plasmalogens function as “scavengers” of
ROS in biological membranes, low levels of ePE are associated
with reduced cell viability because of the cell loss of antioxidant
capacity. Decreased concentrations of ePE may be correlated
with peroxisomal alterations because the enzymes required for
its biosynthesis are found in these organelles (Lizard et al., 2012).
Several studies have reported alterations in peroxisomes isolated
from AD brains and reduced biosynthesis of plasmalogens
composed of DHA (Kou et al., 2011; Fanelli et al., 2013).
Furthermore, the main ePE degradation enzyme is PLA2, which
is significantly increased in AD. Interestingly, in this work, we
demonstrated that BACE1 silencing restored the amount of ePE
in the hippocampus of 3xTg-AD mice to the control levels,
suggesting that BACE1 silencing may play a role in the regulation
of PLA2 activity restoring the homeostasis of this plasmalogen
and allowing it to reach effective concentrations for antioxidant
activity.
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In summary, our study suggests that AD is associated with a
general disruption of membrane properties and a plasmalogens
composition disbalance. The length and saturation number
are important determinants of many membrane characteristics
including membrane, fluidity, thickness and the local curvature,
even molecular packing, which in turn regulate the activities
of the enzyme membrane. Intramembrane proteolysis is likely
to be exquisitely regulated by the thickness of the membrane
(Hong, 2015), which could have implications for β-secretase-
mediated cleavage of APP. However, this work suggests by the
first time that BACE1 is involved in FA composition of PE-
derivates (LPE and ePE), and that the shBACE1miR treatment
in 3xTg-AD mice restores the levels of lipid subspecies that
are altered by the disease in the animal model, preventing pro-
inflammatory signaling, which could be associated the reduction
of tauopathy and with the learning and memory improvement.
However, further research is necessary to establish whether there
is a direct or indirect correlation between the BACE1 levels and
the metabolic pathways of PE, LPE, and ePE and to explain how
BACE1 silencing favors the appearance of the PUFAs involved
in neuroprotection or if the reduction of BACE1 attenuated
cytotoxic βA production for restoring cellular function including
lipid metabolism, anti-inflammatory pathway and cognitive
function, and to verify which would be the analog modulation
of the phospholipid profile and composition in the human AD
pathogenesis.
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